Q3 2024 EPS Estimates for Equillium, Inc. (NASDAQ:EQ) Raised by Analyst

Equillium, Inc. (NASDAQ:EQ) – Investment analysts at Leerink Partnrs boosted their Q3 2024 EPS estimates for shares of Equillium in a research note issued on Monday, March 25th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn $0.58 per share for the quarter, up from their prior forecast of $0.50. The consensus estimate for Equillium’s current full-year earnings is ($0.15) per share. Leerink Partnrs also issued estimates for Equillium’s Q4 2024 earnings at $0.03 EPS and FY2028 earnings at $2.32 EPS.

Separately, HC Wainwright dropped their target price on shares of Equillium from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, December 26th.

Equillium Price Performance

NASDAQ:EQ opened at $2.06 on Thursday. The company has a 50-day moving average of $1.95 and a 200-day moving average of $1.11. Equillium has a 52 week low of $0.45 and a 52 week high of $3.25.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. bought a new position in Equillium during the 1st quarter worth approximately $1,182,000. Renaissance Technologies LLC boosted its stake in Equillium by 913.5% during the 2nd quarter. Renaissance Technologies LLC now owns 392,231 shares of the company’s stock worth $294,000 after acquiring an additional 353,531 shares during the last quarter. State Street Corp boosted its stake in Equillium by 13.2% during the 1st quarter. State Street Corp now owns 56,220 shares of the company’s stock worth $177,000 after acquiring an additional 6,564 shares during the last quarter. Jane Street Group LLC bought a new position in Equillium during the 1st quarter worth approximately $47,000. Finally, Dimensional Fund Advisors LP bought a new position in Equillium during the 3rd quarter worth approximately $43,000. Institutional investors own 27.05% of the company’s stock.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.